Investigational Drug Details
| Drug ID: | D265 |
| Drug Name: | Pemafibrate |
| Synonyms: | Pemafibrate |
| Type: | Chemical drug |
| DrugBank ID: | DB15212 |
| DrugBank Description: | Pemafibrate is under investigation in clinical trial NCT03350165 (A Study of Pemafibrate in Patients With Nonalcoholic Fatty Liver Disease (NAFLD)). |
| PubChem ID: | 11526038 |
| CasNo: | 848259-27-8 |
| Repositioning for NAFLD: | No |
| SMILES: | CC[C@](OC1=CC=CC(CN(C2=NC3=CC=CC=C3O2)CCCOC4=CC=C(OC)C=C4)=C1)([H])C(O)=O |
| Structure: |
|
| InChiKey: | ZHKNLJLMDFQVHJ-RUZDIDTESA-N |
| Molecular Weight: | 490.556 |
| DrugBank Targets: | -- |
| DrugBank MoA: | -- |
| DrugBank Pharmacology: | -- |
| DrugBank Indication: | -- |
| Targets: | PPARA modulator |
| Therapeutic Category: | Anti-inflammatory |
| Clinical Trial Progress: | Phase 2 completed (NCT03350165: Pemafibrate did not decrease liver fat content but had significant reduction in MRE-based liver stiffness. Pemafibrate may be a promising therapeutic agent for NAFLD/NASH, and also be a candidate for combination therapy with agents that reduce liver fat content.) |
| Latest Progress: | Under clinical trials |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0010 | NCT03350165 | Phase 2 | Completed | No Results Available | December 27, 2017 | April 9, 2021 | Details |
| L0401 | JPRN-jRCTs031200280 | Phase 2 | Recruiting | No Results Available | 28/12/2020 | 17 May 2021 | Details |
| L0445 | JPRN-jRCT1041190098 | Not applicable | Recruiting | No Results Available | 17/12/2019 | 10 January 2022 | Details |
| L0485 | JPRN-UMIN000035248 | Not selected | Recruiting | No Results Available | 13/12/2018 | 2 April 2019 | Details |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S05 | Anti-inflammatory | inflammatory | Bile acid; TNF-a inhibitor; Dual PPAR-α and -δ agonists; Toll-Like Receptor; (TLR)-4 antagonist; Caspase inhibitor; ASK-1 inhibitor | Ursodeoxycholic Acid; Pentoxifylline; Elafibranor; JKB-121; Emricasan; Selonsertib; | Details |
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A00165 | 35203610 | Biomedicines | Effects of a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator, Pemafibrate, on Metabolic Parameters: A Retrospective Longitudinal Study. | Details |
| A00877 | 34943553 | Diagnostics (Basel) | Pemafibrate Ameliorates Liver Dysfunction and Fatty Liver in Patients with Non-Alcoholic Fatty Liver Disease with Hypertriglyceridemia: A Retrospective Study with the Outcome after a Mid-Term Follow-Up. | Details |
| A01773 | 34622006 | JGH Open | Effect of 48-week pemafibrate on non-alcoholic fatty liver disease with hypertriglyceridemia, as evaluated by the FibroScan-aspartate aminotransferase score. | Details |
| A02022 | 34528723 | Aliment Pharmacol Ther | Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), versus placebo in patients with non-alcoholic fatty liver disease. | Details |
| A02657 | 34295984 | Clin Exp Hepatol | Pemafibrate improves hepatic inflammation, function and fibrosis in patients with non-alcoholic fatty liver disease: a one-year observational study. | Details |
| A03683 | 33903148 | Gut | Integrative study of diet-induced mouse models of NAFLD identifies PPARα as a sexually dimorphic drug target. | Details |
| A04448 | 33612679 | Intern Med | Impact of Pemafibrate in Patients with Hypertriglyceridemia and Metabolic Dysfunction-associated Fatty Liver Disease Pathologically Diagnosed with Non-alcoholic Steatohepatitis: A Retrospective, Single-arm Study. | Details |
| A05052 | 33392801 | Curr Atheroscler Rep | Selective Peroxisome Proliferator-Activated Receptor Alpha Modulators (SPPARMα) in the Metabolic Syndrome: Is Pemafibrate Light at the End of the Tunnel? | Details |
| A05449 | 33253343 | Yonago Acta Med | Erratum for Ikeda et al., "Pemafibrate Dramatically Ameliorated the Values of Liver Function Tests and Fibrosis Marker in Patients with Non-Alcoholic Fatty Liver Disease". | Details |
| A05710 | 33145434 | Clin Exp Hepatol | Pemafibrate decreases markers of hepatic inflammation in patients with non-alcoholic fatty liver disease. | Details |
| A06330 | 32926754 | Hepatol Res | Effect of pemafibrate on fatty acid levels and liver enzymes in non-alcoholic fatty liver disease patients with dyslipidemia: A single-arm, pilot study. | Details |
| A06427 | 32884438 | Yonago Acta Med | Pemafibrate Dramatically Ameliorated the Values of Liver Function Tests and Fibrosis Marker in Patients with Non-Alcoholic Fatty Liver Disease. | Details |
| A07125 | 32613381 | Cell Biol Toxicol | Human hepatic in vitro models reveal distinct anti-NASH potencies of PPAR agonists. | Details |
| A07703 | 32385406 | Sci Rep | Pemafibrate, a selective PPARα modulator, prevents non-alcoholic steatohepatitis development without reducing the hepatic triglyceride content. | Details |
| A08327 | 32151660 | Metabolism | Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis. | Details |
| A09774 | 31614690 | Int J Mol Sci | Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence. | Details |
| A13975 | 29662003 | Int J Mol Sci | PPAR Agonists and Metabolic Syndrome: An Established Role? | Details |
| A14771 | 29247356 | J Gastroenterol | Current and future pharmacological therapies for NAFLD/NASH. | Details |
| A16762 | 28195199 | Sci Rep | Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis. | Details |
| A28641 | 35203369 | Cells | Selective PPARα Modulator Pemafibrate and Sodium-Glucose Cotransporter 2 Inhibitor Tofogliflozin Combination Treatment Improved Histopathology in Experimental Mice Model of Non-Alcoholic Steatohepatitis. | Details |